Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study [Meeting Abstract]
dc.authorid | ELVERDI, TUGRUL/0000-0001-9496-5353 | |
dc.authorid | Dogu, Mehmet Hilmi/0000-0001-7237-2637 | |
dc.authorid | Kaynar, Leylagul/0000-0002-2035-9462 | |
dc.authorid | Yigenoglu, Tugce/0000-0001-9962-8882 | |
dc.authorwosid | ELVERDI, TUGRUL/D-4366-2019 | |
dc.authorwosid | Dogu, Mehmet Hilmi/W-2255-2017 | |
dc.authorwosid | Yigenoglu, Tugce/ABF-6595-2021 | |
dc.authorwosid | Kaynar, Leylagul/F-6991-2013 | |
dc.contributor.author | Ozbalak, Murat | |
dc.contributor.author | Akay, Olga Meltem | |
dc.contributor.author | Pehlivan, Mustafa | |
dc.contributor.author | Yildiz, Birol | |
dc.contributor.author | Uzay, Ant | |
dc.contributor.author | Yigenoglu, Tugce Nur | |
dc.contributor.author | Elverdi, Tugrul | |
dc.date.accessioned | 2023-01-12T20:22:18Z | |
dc.date.available | 2023-01-12T20:22:18Z | |
dc.date.issued | 2021 | |
dc.department | N/A/Department | en_US |
dc.description.abstract | [No Abstract Available] | en_US |
dc.identifier.endpage | S369 | en_US |
dc.identifier.issn | 2152-2650 | |
dc.identifier.issn | 2152-2669 | |
dc.identifier.startpage | S368 | en_US |
dc.identifier.uri | https://hdl.handle.net/11454/79395 | |
dc.identifier.volume | 21 | en_US |
dc.identifier.wos | WOS:000691910500283 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Cig Media Group, Lp | en_US |
dc.relation.ispartof | Clinical Lymphoma Myeloma & Leukemia | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | relapsed and refractory | en_US |
dc.subject | Hodgkin lymphoma | en_US |
dc.subject | brentuximab vedotin | en_US |
dc.subject | autologous stem cell transplantation | en_US |
dc.subject | consolidation | en_US |
dc.title | Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study [Meeting Abstract] | en_US |
dc.type | Conference Object | en_US |